An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 17, Issue 1, 2017, Pages 85-98

  Largeron, Nathalie ^a   Petry, Karl Ulrich ^b   Jacob, Jorge ^c   Bianic, Florence ^c   Anger, Delphine ^c   Uhart, Mathieu ^a  

^a SANOFI PASTEUR   (France)

^b Klinikum Wolfsburg   (Germany)

^c MAPI GROUP   (Netherlands)

Author keywords

cervical cancer; Cost effectiveness; Germany; HPV; vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ANUS CANCER; ARTICLE; CANCER MORTALITY; CHILD; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; FEMALE; GERMANY; HEAD AND NECK CANCER; HEALTH IMPACT ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PENIS CANCER; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; TREATMENT PLANNING; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; ANUS NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADOLESCENT; ANUS NEOPLASMS; CHILD; COST-BENEFIT ANALYSIS; FEMALE; GERMANY; HUMANS; IMMUNIZATION PROGRAMS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PUBLIC HEALTH; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84978513126     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1080/14737167.2016.1208087     Document Type: Article

References (83)

1. Hartwig S, Baldauf JJ, Dominiak-Felden G., Estimation of the epidemiological burden of HPV-related cancers, precancerous lesions, and genital warts in women and men in Europe:potential additional benefit of a nine-valent compared to the quadrivalent HPV vaccine. Papillomavirus Res. 2015;1:90–100.• Provides an overview of the percentage of HPV-related diseases attributable to the genotypes included in both vaccines.
2. Robert Koch Institute. Geman Centre for Registry Cancer Data (Zentrum für Krebsregisterdaten - ZfKD). 2014 [cited 2014 Feb17]. Available from:http://www.krebsdaten.de/Krebs/DE/Content/ZfKD/zfkd_node.html
3. NHS.uk. What is HPV? Berlin:Robert Koch Institute; 2015.
4. Introduction of HPV vaccines in European Union countries - an update. European Centre for Disease Prevention and Control [Internet]. London:National Health Services; 2015 [cited 2016 Jul 7]. Available from:http://www.nhs.uk/chq/Pages/2611.aspx.
5. Aubin F, Prétet J-L, Jacquard A-C, et al. Human papillomavirus genotype distribution in external acuminata condylomata:a large French National Study (EDiTH IV). Clin Infect Dis. 2008;47(5):610–615.
6. Menton JF, Cheng A, Wang M, et al. Molecular epidemiology of sexually transmitted human papillomavirus in a self referred group of women in Ireland. Virol J. 2009;6:112.
7. Preaud E, Largeron N. Economic burden of non-cervical cancers attributable to human papillomavirus:a European scoping review. J Med Econ. 2013;16(6):763–776.
8. Kotsopoulos N, Connolly MP, Remy V. Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework. Health Econ Rev. 2015;5(1):54.
9. Horn J, Damm O, Kretzschmar MEE, et al. Estimating the long-term effects of HPV vaccination in Germany. Vaccine. 2013;31(19):2372–2380.•• Assesses the public health benefits of a universal vaccination program against HPV in Germany.
10. Seidel D, Becker N, Rohrmann S, et al. Socio-demographic characteristics of participation in the opportunistic German cervical cancer screening programme:results from the EPIC-Heidelberg cohort. J Cancer Res Clin Oncol. 2009;135(4):533–541.
11. Hillemanns P, Mallmann P, Beckmann MW. New screening proposals:the federal joint commission defines the parameters for cervical cancer screening from 2018:statement of the gynecology oncology working group (AGO). Geburtshilfe Frauenheilkd. 2016;76(2):145–146.
12. European Medicine Agency - Committee for Medicinal Products for Human Use. Gardasil human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) - Summary of opinion. European Medicine Agency, Committee for Medicinal Products for Human Use. London:European Medicine Agency.
13. European Medicines Agency. Gardasil, Summary of Product Characteristics [Internet]. 2015 [cited 2016 Jul 7]. Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp
14. European Medicines Agency. Cervarix, summary of product characteristics. 2015 [cited 2016 Jul 7]. Available from:http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124
15. Rieck T, Feig M, Deleré Y, et al. Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. Vaccine. 2014;32(43):5564–5569.
16. Hense S, Hillebrand K, Horn J, et al. HPV vaccine uptake after introduction of the vaccine in Germany:an analysis of administrative data. Hum Vaccin Immunother. 2014;10(6):1729–1733.
17. Delere Y, Böhmer MM, Walter D, et al. HPV vaccination coverage among women aged 18-20 years in Germany three years after recommendation of HPV vaccination for adolescent girls:results from a cross-sectional survey. Hum Vaccin Immunother. 2013;9(8):1706–1711.
18. Robert Koch Institute. Recommendations of the standing committee on vaccination (STIKO) at the Robert Koch Institute /effective:August 2014. Berlin:Robert Koch Institute; 2015.
19. Poethko-Muller C, Buttmann-Schweiger N, Ki GGSSG. [HPV vaccination coverage in German girls:results of the KiGGS study:first follow-up (KiGGS Wave 1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(7):869–877.
20. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide:Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–935.
21. Merck. Merck’s investigational 9-valent HPV vaccine, V503, prevented 97 percent of cervical, vaginal and vulvar pre-cancers caused by five additional HPV types, in phase III study. 2015 [cited 2014 Dec1]; Available from:http://www.mercknewsroom.com/news-release/research-and-development-news/mercks-investigational-9-valent-hpv-vaccine-v503-prevente
22. Summary of opinion Gardasil 9 human papillomavirus 9-valent vaccine (recombinant, adsorbed). 2015, European Medicine Agency, Committee for Medicinal Products for Human Use.
23. Jit M. Cost effectiveness of elimination of HPV-related cancers, in 5th Helsinki HPV workshop on vaccination women and men against premature death. Helsinki:Helsinki HPV Seminar; 2016.
24. Brisson M. Incremental cost-effectiveness of the 9-valent vs. the 4-valent HPV vaccine in the U.S., in Advisory Committee on Immunization Practices (ACIP) meeting. Atlanta:ACIP; 2014.
25. Weiss TP, Dasbach M, Potential health and economic impact of the investigational 9-valent HPV vaccine in the United States, In International Papillomavirus Conference. 2014:Seattle.
26. Chesson H. Overview of cost-effectiveness of 9-valent HPV vaccination, in Advisory Committee on Immunization Practices. Atlanta; 2015.
27. Drolet M, Laprise J-F, Boily M-C, et al. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;134(9):2264–2268.
28. Boiron L, Joura E, Largeron N, et al. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent Hpv vaccine in Austria. Value in Health. 2015;18(7):A585.
29. Hillemanns P, Petry KU, Largeron N, et al. Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Public Health. 2009;17:77–86.
30. Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev. 2012;2(1):19.• Reports the methods and results of the German adaptation performed on a previous version of the same model used in this study
31. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28–41.•• Describes in detail the structure of the first version of the model used in this study
32. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858–6867.• Provides input values for model key parameters
33. Elbasha EH, Dasbach EJ. An integrated economic evaluation and HPV disease transmission models - technical report accompanying the manuscript impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858–6867.
34. German Federal Statistics Office. Facts & figures -> society & state ->population ->deaths, life expectancy. https://www.destatis.de/EN/FactsFigures/SocietyState/Population/Deaths/Deaths.html;jsessionid=4F274DF95FF7F226BB3576989FBA7AE7.cae2 [Internet]. 2015 [cited 2016 Jul 7]. Available from:https://www.destatis.de/EN/FactsFigures/SocietyState/Population/Deaths/Deaths.html
35. National Survey of Sexual Attitudes and Life Styles III. N.S.f.S. Research, Editor. London:NATSAL.
36. Federal Statistics Office (Statistisches Bundesamt), Fallpauschalenbezogene Krankenhausstatistik (DRG-Statistik) Diagnosen, Prozeduren, Fallpauschalen und Case Mix der vollstationären Patientinnen und Patienten in Krankenhäusern [Internet]. 2014 [cited 2016 Jul 7]. Avaliable from:https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Krankenhaeuser/OperationenProzeduren5231401137014.pdf?__blob=publicationFile
37. Sroczynski G, Schnell-Inderst P, Mühlberger N, et al. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess. 2010;6:Doc05.
38. Rϋckinger S, Tauscher M, Redel R, et al. Participation in cervical cancer screening by age and region–a cohort study with a 3 1/2 year follow-up on 2,223,135 women in Bavaria. Gesundheitswesen. 2008;70(6):e17–e21.
39. Kerek-Bodden HA, Brenner GL, Durchführung einer versichertenbezogenen Untersuchung zur Inanspruchnahme der Früherkennung auf Zervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von Abrechnungsdaten [Internet]. 2008 [cited 2016 Jul 7]. http://www.ag-cpc.de/media/ZI-Abschlussbericht-080602.pdf
40. McCrory DC, Matchar DB, Bastian L, et al. Evaluation of cervical cytology. Evid Rep Technol Assess (Summ). 1999;5:1–6.
41. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities:a systematic review. Ann Intern Med. 2000;132(10):810–819.
42. Mitchell MF, Schottenfeld D, Tortolero-Luna G, et al. Colposcopy for the diagnosis of squamous intraepithelial lesions:a meta-analysis. Obstet Gynecol. 1998;91(4):626–631.
43. Insinga RP, Dasbach EJ, Elbasha EH, et al. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer. 2007;2:15.
44. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151(12):1158–1171.
45. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9(1):37–48.
46. Ho GY, Studentsov YY, Bierman R, et al. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev. 2004;13(1):110–116.
47. Onda T, Carter JJ, Koutsky LA, et al. Characterization of IgA response among women with incident HPV 16 infection. Virology. 2003;312(1):213–221.
48. Federal Statistics Office (Statistisches Bundesamt). Mortality Table Germany 2010-12 [Internet]. 2015 [cited 2016 Jul 7]. Available from:https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Sterbefaelle/Tabellen/SterbetafelDeutschland.xlsx?__blob=publicationFile
49. German Federal Statiscs Office. Facts & figures -> society & state ->population ->current population. 2015 [cited 2015; Available from:https://www.destatis.de/EN/FactsFigures/SocietyState/Population/CurrentPopulation/CurrentPopulation.html
50. Zechmeister I, Blasio, BF, Garnett G, et al. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009;27(37):5133–5141.
51. Schmitt DP. Sociosexuality from Argentina to Zimbabwe:a 48-nation study of sex, culture, and strategies of human mating. Behav Brain Sci. 2005;28(2):247–275.
52. Petry KU, Page K, Stein ES, et al. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 -results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis. 2012;12:367.
53. Petry KU, Luyten A, Justus A, et al. Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84–results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis. 2013;13:135.
54. Luyten A, Buttmann-Schweiger N, Luyten K, et al. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. Int J Cancer. 2014;135(6):1408–1416.
55. Cancer Research UK. Cervical cancer survival statistics. [cited 2014 Nov27. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/cervix/survival/2014
56. Istituto Nazionale Tumori and Istituto Superiore di Sanità, Eurocare Survival of cancer patient in Europe [Internet]. 2015 [cited 2016 Jul 7]. Available from:http://www.eurocare.it/.
57. Joura EA, Giuliano AR, Iversen O-E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723.
58. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ:a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861–1868.
59. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–1943.
60. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401–411.
61. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions:a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693–1702.
62. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–1585.
63. Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–1927.
64. Federal Statiscs Office (Statistisches Bundesamt). German consumer price index (CPI). 2015 [cited 2015 Aug12]; Available from:https://www.destatis.de/EN/FactsFigures/NationalEconomyEnvironment/Prices/ConsumerPriceIndices/Tables_/ConsumerPricesCategories.html?cms_gtp=151232_list%253D3%2526151226_slot%253D2&https=1
65. Petry KU, Breugelmans JG, Bénard S, et al. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol. 2008;29(4):345–349.
66. Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800–804.
67. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198(5):500–507.
68. Siebert U, Muth C, Sroczynski G, et al. Liquid-based preparation and computer-assisted examination of cervical smears. Clinical effectiveness, economic evaluation and systematic decision analysis. Health Technol Assess. 2004;1–444. https://www.mig.tu-berlin.de/fileadmin/a38331600/2004.publications/2004.siebert_hta.35.pdf in Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security
69. Hampl M, Hahn JA, Delwart E, et al. Economic burden of vulvar and vaginal intraepithelial neoplasia:retrospective cost study at a German dysplasia centre. BMC Infect Dis. 2011;11:73.
70. Brisson M, Laprise J-F, Drolet M, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines:a transmission-dynamic modeling study. Vaccine. 2013;31(37):3863–3871.
71. Hillemanns P, Breugelmans JG, Gieseking F, et al. Estimation of the incidence of genital warts and the cost of illness in Germany:a cross-sectional study. BMC Infect Dis. 2008;8:76.
72. Rote Liste Service GmbH. Gardasil Price. 2016 [cited 2016 Feb08]; Available from:http://online.rote-liste.de/suche/praep/20976
73. Lauer Fischer. Gardasil 9 Price. 2016. [cited 2016 March15]. Available from:http://www2.lauer- fischer.de/produkte/lauer-taxe/lauer-taxe/
74. Hinz A, Klaiberg A, Brähler E, et al. The Quality of Life Questionnaire EQ-5D:modelling and norm values for the general population. Psychother Psychosom Med Psychol. 2006;56(2):42–48.
75. Klussmann JP, Schädlich PK, Chen X, et al. Annual cost of hospitalization, inpatient rehabilitation, and sick leave for head and neck cancers in Germany. Clinicoecon Outcomes Res. 2013;5:203–213.
76. Kraut AA, Schink T, Schulze-Rath R, et al. Incidence of anogenital warts in Germany:a population-based cohort study. BMC Infect Dis. 2010;10:360.
77. Hartwig S, Syrjänen S, Dominiak-Felden G, et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe:a review. BMC Cancer. 2012;12:30.
78. Health & Social Care Information Centre, Cervical Screening Programme, England 2013-14. 2015.
79. Population Estimates for UK, England and Wales, Scotland and Northern Ireland, Mid-2013. 2014 [cited 2014 Jan19]. Available from:http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-322718
80. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions:systematic review and meta-analysis. Lancet. 2006;367(9509):489–498.
81. Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix:a systematic review and meta-analysis. BJOG. 2011;118(9):1031–1041.
82. Soergel P, Makowski L, Schippert C, et al. The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. Hum Vaccin Immunother. 2012;8(2):243–251.
83. Lerner D, Parsons SK, Justicia-Linde F, et al. The impact of precancerous cervical lesions on functioning at work and work productivity. J Occup Environ Med. 2010;52(9):926–933.